{"id":89647,"date":"2024-10-25T11:45:05","date_gmt":"2024-10-25T09:45:05","guid":{"rendered":"https:\/\/www.anderapartners.com\/?p=89647"},"modified":"2024-10-25T12:01:36","modified_gmt":"2024-10-25T10:01:36","slug":"agomab-announces-89-million-series-d-financing-to-support-broad-fibrosisfocused-pipeline","status":"publish","type":"post","link":"https:\/\/www.anderapartners.com\/fr\/agomab-announces-89-million-series-d-financing-to-support-broad-fibrosisfocused-pipeline\/","title":{"rendered":"Agomab Announces $89 Million Series D Financing to Support Broad Fibrosis-focused Pipeline"},"content":{"rendered":"

Agomab Therapeutics NV<\/strong> (\u2018Agomab\u2019) today announced a $89 million (\u20ac82.1 million) Series D financing round, with participation from new investors Sanofi and Invus, as well as existing investors.<\/p>\n

The proceeds from the Series D will be used to further advance the ongoing clinical development of Agomab\u2019s lead candidate, AGMB-129, a gut-restricted oral small molecule inhibitor of ALK5 (TGF\u03b21R), in patients with fibrostenosing Crohn\u2019s disease (FSCD). Interim data from the Phase 2a STENOVA trial are expected in the first quarter of 2025. In addition, proceeds will be used to advance the clinical development for AGMB-447, a lung-restricted inhaled small molecule inhibitor of ALK5, that is currently in a Phase 1 clinical trial in healthy subjects and patients with idiopathic pulmonary fibrosis (IPF), as well as initial clinical development of AGMB-101, a full MET agonistic antibody currently in the final stages of IND-enabling studies, which the company intends to develop for liver cirrhosis.<\/p>\n

\u201cWe are thrilled to have Sanofi and Invus joining our investor syndicate. Their investment as well as the continued support from our existing shareholders is another validation of the trailblazing work our team is conducting in the fields of fibrostenosing Crohn\u2019s disease and idiopathic pulmonary fibrosis.\u201d said Tim Knotnerus, Chief Executive Officer at Agomab Therapeutics.<\/strong> \u201cThrough this financing round we will create further optionality and the capital will allow us to accelerate our efforts in developing our novel potential therapies.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"

Agomab Therapeutics NV (\u2018Agomab\u2019) today announced a $89 million (\u20ac82.1 million) Series D financing round, with participation from new investors Sanofi and Invus, as well as existing investors. The proceeds from the Series D will be used to further advance the ongoing clinical development of Agomab\u2019s lead candidate, AGMB-129, a gut-restricted oral small molecule inhibitor…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[123],"class_list":["post-89647","post","type-post","status-publish","format-standard","hentry","category-biodiscovery-en"],"acf":[],"yoast_head":"\nAgomab Announces $89 Million Series D Financing to Support Broad Fibrosis-focused Pipeline - ANDERA PARTNERS<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.anderapartners.com\/en\/agomab-announces-89-million-series-d-financing-to-support-broad-fibrosisfocused-pipeline\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Agomab Announces $89 Million Series D Financing to Support Broad Fibrosis-focused Pipeline - ANDERA PARTNERS\" \/>\n<meta property=\"og:description\" content=\"Agomab Therapeutics NV (\u2018Agomab\u2019) today announced a $89 million (\u20ac82.1 million) Series D financing round, with participation from new investors Sanofi and Invus, as well as existing investors. The proceeds from the Series D will be used to further advance the ongoing clinical development of Agomab\u2019s lead candidate, AGMB-129, a gut-restricted oral small molecule inhibitor...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.anderapartners.com\/en\/agomab-announces-89-million-series-d-financing-to-support-broad-fibrosisfocused-pipeline\/\" \/>\n<meta property=\"og:site_name\" content=\"ANDERA PARTNERS\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-25T09:45:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-25T10:01:36+00:00\" \/>\n<meta name=\"author\" content=\"Nicolas Delsert\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nicolas Delsert\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/agomab-announces-89-million-series-d-financing-to-support-broad-fibrosisfocused-pipeline\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/agomab-announces-89-million-series-d-financing-to-support-broad-fibrosisfocused-pipeline\/\"},\"author\":{\"name\":\"Nicolas Delsert\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\"},\"headline\":\"Agomab Announces $89 Million Series D Financing to Support Broad Fibrosis-focused Pipeline\",\"datePublished\":\"2024-10-25T09:45:05+00:00\",\"dateModified\":\"2024-10-25T10:01:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/agomab-announces-89-million-series-d-financing-to-support-broad-fibrosisfocused-pipeline\/\"},\"wordCount\":242,\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"articleSection\":[\"andera Life Sciences\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/agomab-announces-89-million-series-d-financing-to-support-broad-fibrosisfocused-pipeline\/\",\"url\":\"https:\/\/www.anderapartners.com\/en\/agomab-announces-89-million-series-d-financing-to-support-broad-fibrosisfocused-pipeline\/\",\"name\":\"Agomab Announces $89 Million Series D Financing to Support Broad Fibrosis-focused Pipeline - ANDERA PARTNERS\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\"},\"datePublished\":\"2024-10-25T09:45:05+00:00\",\"dateModified\":\"2024-10-25T10:01:36+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/agomab-announces-89-million-series-d-financing-to-support-broad-fibrosisfocused-pipeline\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.anderapartners.com\/en\/agomab-announces-89-million-series-d-financing-to-support-broad-fibrosisfocused-pipeline\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/agomab-announces-89-million-series-d-financing-to-support-broad-fibrosisfocused-pipeline\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.anderapartners.com\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Agomab Announces $89 Million Series D Financing to Support Broad Fibrosis-focused Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"name\":\"ANDERA PARTNERS\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\",\"name\":\"Andera Partners\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"contentUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"width\":107,\"height\":44,\"caption\":\"Andera Partners\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\",\"name\":\"Nicolas Delsert\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"caption\":\"Nicolas Delsert\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Agomab Announces $89 Million Series D Financing to Support Broad Fibrosis-focused Pipeline - ANDERA PARTNERS","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.anderapartners.com\/en\/agomab-announces-89-million-series-d-financing-to-support-broad-fibrosisfocused-pipeline\/","og_locale":"fr_FR","og_type":"article","og_title":"Agomab Announces $89 Million Series D Financing to Support Broad Fibrosis-focused Pipeline - ANDERA PARTNERS","og_description":"Agomab Therapeutics NV (\u2018Agomab\u2019) today announced a $89 million (\u20ac82.1 million) Series D financing round, with participation from new investors Sanofi and Invus, as well as existing investors. The proceeds from the Series D will be used to further advance the ongoing clinical development of Agomab\u2019s lead candidate, AGMB-129, a gut-restricted oral small molecule inhibitor...","og_url":"https:\/\/www.anderapartners.com\/en\/agomab-announces-89-million-series-d-financing-to-support-broad-fibrosisfocused-pipeline\/","og_site_name":"ANDERA PARTNERS","article_published_time":"2024-10-25T09:45:05+00:00","article_modified_time":"2024-10-25T10:01:36+00:00","author":"Nicolas Delsert","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Nicolas Delsert","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.anderapartners.com\/en\/agomab-announces-89-million-series-d-financing-to-support-broad-fibrosisfocused-pipeline\/#article","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/en\/agomab-announces-89-million-series-d-financing-to-support-broad-fibrosisfocused-pipeline\/"},"author":{"name":"Nicolas Delsert","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c"},"headline":"Agomab Announces $89 Million Series D Financing to Support Broad Fibrosis-focused Pipeline","datePublished":"2024-10-25T09:45:05+00:00","dateModified":"2024-10-25T10:01:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.anderapartners.com\/en\/agomab-announces-89-million-series-d-financing-to-support-broad-fibrosisfocused-pipeline\/"},"wordCount":242,"publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"articleSection":["andera Life Sciences"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.anderapartners.com\/en\/agomab-announces-89-million-series-d-financing-to-support-broad-fibrosisfocused-pipeline\/","url":"https:\/\/www.anderapartners.com\/en\/agomab-announces-89-million-series-d-financing-to-support-broad-fibrosisfocused-pipeline\/","name":"Agomab Announces $89 Million Series D Financing to Support Broad Fibrosis-focused Pipeline - ANDERA PARTNERS","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/fr\/#website"},"datePublished":"2024-10-25T09:45:05+00:00","dateModified":"2024-10-25T10:01:36+00:00","breadcrumb":{"@id":"https:\/\/www.anderapartners.com\/en\/agomab-announces-89-million-series-d-financing-to-support-broad-fibrosisfocused-pipeline\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.anderapartners.com\/en\/agomab-announces-89-million-series-d-financing-to-support-broad-fibrosisfocused-pipeline\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.anderapartners.com\/en\/agomab-announces-89-million-series-d-financing-to-support-broad-fibrosisfocused-pipeline\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.anderapartners.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Agomab Announces $89 Million Series D Financing to Support Broad Fibrosis-focused Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/www.anderapartners.com\/fr\/#website","url":"https:\/\/www.anderapartners.com\/fr\/","name":"ANDERA PARTNERS","description":"","publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.anderapartners.com\/fr\/#organization","name":"Andera Partners","url":"https:\/\/www.anderapartners.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","contentUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","width":107,"height":44,"caption":"Andera Partners"},"image":{"@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c","name":"Nicolas Delsert","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","caption":"Nicolas Delsert"}}]}},"_links":{"self":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts\/89647","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/comments?post=89647"}],"version-history":[{"count":2,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts\/89647\/revisions"}],"predecessor-version":[{"id":89650,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts\/89647\/revisions\/89650"}],"wp:attachment":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/media?parent=89647"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/categories?post=89647"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}